<author><surname>Buning</surname> <given-names>H</given-names> </author><author><surname>Perabo</surname> <given-names>L</given-names> </author><author><surname>Coutelle</surname> <given-names>O</given-names> </author><author><surname>Quadt-Humme</surname> <given-names>S</given-names> </author><author><surname>Hallek</surname> <given-names>M</given-names> </author><title>Recent developments in adeno-associated virus vector technology</title><source>J Gene Med</source><year>2008</year><volume>10</volume><fpage>717</fpage><lpage>733</lpage>
<author><surname>Wu</surname> <given-names>Z</given-names> </author><author><surname>Asokan</surname> <given-names>A</given-names> </author><author><surname>Samulski</surname> <given-names>RJ</given-names> </author><title>Adeno-associated virus serotypes: vector toolkit for human gene therapy</title><source>Mol Ther</source><year>2006</year><volume>14</volume><fpage>316</fpage><lpage>327</lpage>
<author><surname>Lebherz</surname> <given-names>C</given-names> </author><author><surname>Maguire</surname> <given-names>A</given-names> </author><author><surname>Tang</surname> <given-names>W</given-names> </author><author><surname>Bennett</surname> <given-names>J</given-names> </author><author><surname>Wilson</surname> <given-names>JM</given-names> </author><title>Novel AAV serotypes for improved ocular gene transfer</title><source>J Gene Med</source><year>2008</year><volume>10</volume><fpage>375</fpage><lpage>382</lpage>
<author><surname>Schmidt</surname> <given-names>M</given-names> </author><author><surname>Voutetakis</surname> <given-names>A</given-names> </author><author><surname>Afione</surname> <given-names>S</given-names> </author><title>Adeno-associated virus type 12 (AAV12): a novel AAV serotype with sialic acid- and heparan sulfate proteoglycan-independent transduction activity</title><source>J Virol</source><year>2008</year><volume>82</volume><fpage>1399</fpage><lpage>1406</lpage>
<author><surname>Blankinship</surname> <given-names>MJ</given-names> </author><author><surname>Gregorevic</surname> <given-names>P</given-names> </author><author><surname>Chamberlain</surname> <given-names>JS</given-names> </author><title>Gene therapy strategies for Duchenne muscular dystrophy utilizing recombinant adeno-associated virus vectors</title><source>Mol Ther</source><year>2006</year><volume>13</volume><fpage>241</fpage><lpage>249</lpage>
<author><surname>Wang</surname> <given-names>L</given-names> </author><author><surname>Herzog</surname> <given-names>RW</given-names> </author><title>AAV-mediated gene transfer for treatment of hemophilia</title><source>Curr Gene Ther</source><year>2005</year><volume>5</volume><fpage>349</fpage><lpage>360</lpage>
<author><surname>Buch</surname> <given-names>PK</given-names> </author><author><surname>Bainbridge</surname> <given-names>JW</given-names> </author><author><surname>Ali</surname> <given-names>RR</given-names> </author><title>AAV-mediated gene therapy for retinal disorders: from mouse to man</title><source>Gene Ther</source><year>2008</year><volume>15</volume><fpage>849</fpage><lpage>857</lpage>
<author><surname>Moss</surname> <given-names>RB</given-names> </author><author><surname>Milla</surname> <given-names>C</given-names> </author><author><surname>Colombo</surname> <given-names>J</given-names> </author><title>Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial</title><source>Hum Gene Ther</source><year>2007</year><volume>18</volume><fpage>726</fpage><lpage>732</lpage>
<author><surname>Manno</surname> <given-names>CS</given-names> </author><author><surname>Pierce</surname> <given-names>GF</given-names> </author><author><surname>Arruda</surname> <given-names>VR</given-names> </author><title>Successful transduction of liver in hemophilia by AAV-Factor IX and limitations imposed by the host immune response</title><source>Nat Med</source><year>2006</year><volume>12</volume><fpage>342</fpage><lpage>347</lpage>
<author><surname>McPhee</surname> <given-names>SW</given-names> </author><author><surname>Janson</surname> <given-names>CG</given-names> </author><author><surname>Li</surname> <given-names>C</given-names> </author><title>Immune responses to AAV in a phase I study for Canavan disease</title><source>J Gene Med</source><year>2006</year><volume>8</volume><fpage>577</fpage><lpage>588</lpage>
<author><surname>Mingozzi</surname> <given-names>F</given-names> </author><author><surname>High</surname> <given-names>KA</given-names> </author><title>Immune responses to AAV in clinical trials</title><source>Curr Gene Ther</source><year>2007</year><volume>7</volume><fpage>316</fpage><lpage>324</lpage>
<author><surname>Erles</surname> <given-names>K</given-names> </author><author><surname>Sebokova</surname> <given-names>P</given-names> </author><author><surname>Schlehofer</surname> <given-names>JR</given-names> </author><title>Update on the prevalence of serum antibodies (IgG and IgM) to adeno-associated virus (AAV)</title><source>J Med Virol</source><year>1999</year><volume>59</volume><fpage>406</fpage><lpage>411</lpage>
<author><surname>Halbert</surname> <given-names>CL</given-names> </author><author><surname>Miller</surname> <given-names>AD</given-names> </author><author><surname>McNamara</surname> <given-names>S</given-names> </author><title>Prevalence of neutralizing antibodies against adeno-associated virus (AAV) types 2, 5, and 6 in cystic fibrosis and normal populations: Implications for gene therapy using AAV vectors</title><source>Hum Gene Ther</source><year>2006</year><volume>17</volume><fpage>440</fpage><lpage>447</lpage>
<author><surname>Mingozzi</surname> <given-names>F</given-names> </author><author><surname>Maus</surname> <given-names>MV</given-names> </author><author><surname>Hui</surname> <given-names>DJ</given-names> </author><title>CD8(+) T-cell responses to adeno-associated virus capsid in humans</title><source>Nat Med</source><year>2007</year><volume>13</volume><fpage>419</fpage><lpage>422</lpage>
<author><surname>Zaiss</surname> <given-names>AK</given-names> </author><author><surname>Muruve</surname> <given-names>DA</given-names> </author><title>Immune responses to adeno-associated virus vectors</title><source>Curr Gene Ther</source><year>2005</year><volume>5</volume><fpage>323</fpage><lpage>331</lpage>
<author><surname>Wang</surname> <given-names>Z</given-names> </author><author><surname>Allen</surname> <given-names>JM</given-names> </author><author><surname>Riddell</surname> <given-names>SR</given-names> </author><title>Immunity to adeno-associated virus-mediated gene transfer in a random-bred canine model of Duchenne muscular dystrophy</title><source>Hum Gene Ther</source><year>2007</year><volume>18</volume><fpage>18</fpage><lpage>26</lpage>
<author><surname>Yuasa</surname> <given-names>K</given-names> </author><author><surname>Yoshimura</surname> <given-names>M</given-names> </author><author><surname>Urasawa</surname> <given-names>N</given-names> </author><title>Injection of a recombinant AAV serotype 2 into canine skeletal muscles evokes strong immune responses against transgene products</title><source>Gene Ther</source><year>2007</year><volume>14</volume><fpage>1249</fpage><lpage>1260</lpage>
<author><surname>Cao</surname> <given-names>O</given-names> </author><author><surname>Dobrzynski</surname> <given-names>E</given-names> </author><author><surname>Wang</surname> <given-names>L</given-names> </author><title>Induction and role of regulatory CD4+ CD25+ T cells in tolerance to the transgene product following hepatic in vivo gene transfer</title><source>Blood</source><year>2007</year><volume>110</volume><fpage>1132</fpage><lpage>1140</lpage>
<author><surname>Riviere</surname> <given-names>C</given-names> </author><author><surname>Danos</surname> <given-names>O</given-names> </author><author><surname>Douar</surname> <given-names>AM</given-names> </author><title>Long-term expression and repeated administration of AAV type 1, 2 and 5 vectors in skeletal muscle of immunocompetent adult mice</title><source>Gene Ther</source><year>2006</year><volume>13</volume><fpage>1300</fpage><lpage>1308</lpage>
<author><surname>Streilein</surname> <given-names>JW</given-names> </author><title>Ocular immune privilege: therapeutic opportunities from an experiment of nature</title><source>Nat Rev Immunol</source><year>2003</year><volume>3</volume><fpage>879</fpage><lpage>889</lpage>
<author><surname>Yamagami</surname> <given-names>S</given-names> </author><author><surname>Kawashima</surname> <given-names>H</given-names> </author><author><surname>Tsuru</surname> <given-names>T</given-names> </author><title>Role of Fas&#8211;Fas ligand interactions in the immunorejection of allogeneic mouse corneal transplants</title><source>Transplantation</source><year>1997</year><volume>64</volume><fpage>1107</fpage><lpage>1111</lpage>
<author><surname>Jorgensen</surname> <given-names>A</given-names> </author><author><surname>Wiencke</surname> <given-names>AK</given-names> </author><author><surname>la</surname> <given-names>CM</given-names> </author><title>Human retinal pigment epithelial cell-induced apoptosis in activated T cells</title><source>Invest Ophthalmol Vis Sci</source><year>1998</year><volume>39</volume><fpage>1590</fpage><lpage>1599</lpage>
<author><surname>Camelo</surname> <given-names>S</given-names> </author><author><surname>Kezic</surname> <given-names>J</given-names> </author><author><surname>McMenamin</surname> <given-names>PG</given-names> </author><title>Anterior chamber-associated immune deviation: a review of the anatomical evidence for the afferent arm of this unusual experimental model of ocular immune responses</title><source>Clin Experiment Ophthalmol</source><year>2005</year><volume>33</volume><fpage>426</fpage><lpage>432</lpage>
<author><surname>Sonoda</surname> <given-names>KH</given-names> </author><author><surname>Sakamoto</surname> <given-names>T</given-names> </author><author><surname>Qiao</surname> <given-names>H</given-names> </author><title>The analysis of systemic tolerance elicited by antigen inoculation into the vitreous cavity: vitreous cavity-associated immune deviation</title><source>Immunology</source><year>2005</year><volume>116</volume><fpage>390</fpage><lpage>399</lpage>
<author><surname>Schlichtenbrede</surname> <given-names>FC</given-names> </author><author><surname>da</surname> <given-names>CL</given-names> </author><author><surname>Stephens</surname> <given-names>C</given-names> </author><title>Long-term evaluation of retinal function in Prph2Rd2/Rd2 mice following AAV-mediated gene replacement therapy</title><source>J Gene Med</source><year>2003</year><volume>5</volume><fpage>757</fpage><lpage>764</lpage>
<author><surname>Kjellstrom</surname> <given-names>S</given-names> </author><author><surname>Bush</surname> <given-names>RA</given-names> </author><author><surname>Zeng</surname> <given-names>Y</given-names> </author><author><surname>Takada</surname> <given-names>Y</given-names> </author><author><surname>Sieving</surname> <given-names>PA</given-names> </author><title>Retinoschisin gene therapy and natural history in the Rs1h-KO mouse: long-term rescue from retinal degeneration</title><source>Invest Ophthalmol Vis Sci</source><year>2007</year><volume>48</volume><fpage>3837</fpage><lpage>3845</lpage>
<author><surname>Bainbridge</surname> <given-names>JW</given-names> </author><author><surname>Smith</surname> <given-names>AJ</given-names> </author><author><surname>Barker</surname> <given-names>SS</given-names> </author><title>Effect of gene therapy on visual function in Leber's congenital amaurosis</title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>2231</fpage><lpage>2239</lpage>
<author><surname>Maguire</surname> <given-names>AM</given-names> </author><author><surname>Simonelli</surname> <given-names>F</given-names> </author><author><surname>Pierce</surname> <given-names>EA</given-names> </author><title>Safety and efficacy of gene transfer for Leber's congenital amaurosis</title><source>N Engl J Med</source><year>2008</year><volume>358</volume><fpage>2240</fpage><lpage>2248</lpage>
<author><surname>Pang</surname> <given-names>JJ</given-names> </author><author><surname>Chang</surname> <given-names>B</given-names> </author><author><surname>Hawes</surname> <given-names>NL</given-names> </author><title>Retinal degeneration 12 (rd12): a new, spontaneously arising mouse model for human Leber congenital amaurosis (LCA)</title><source>Mol Vis</source><year>2005</year><volume>11</volume><fpage>152</fpage><lpage>162</lpage>
<author><surname>Mistry</surname> <given-names>AR</given-names> </author><author><surname>De</surname> <given-names>AM</given-names> </author><author><surname>Feudner</surname> <given-names>E</given-names> </author><author><surname>Ali</surname> <given-names>RR</given-names> </author><author><surname>Thrasher</surname> <given-names>AJ</given-names> </author><title>High-titer stocks of adeno-associated virus from replicating amplicons and herpes vectors</title><source>Methods Mol Med</source><year>2002</year><volume>69</volume><fpage>445</fpage><lpage>460</lpage>
<author><surname>Rogers</surname> <given-names>WO</given-names> </author><author><surname>Weaver</surname> <given-names>CT</given-names> </author><author><surname>Kraus</surname> <given-names>LA</given-names> </author><title>Visualization of antigen-specific T cell activation and cytokine expression in vivo</title><source>J Immunol</source><year>1997</year><volume>158</volume><fpage>649</fpage><lpage>657</lpage>
<author><surname>Leonard</surname> <given-names>WJ</given-names> </author><author><surname>Kronke</surname> <given-names>M</given-names> </author><author><surname>Peffer</surname> <given-names>NJ</given-names> </author><author><surname>Depper</surname> <given-names>JM</given-names> </author><author><surname>Greene</surname> <given-names>WC</given-names> </author><title>Interleukin 2 receptor gene expression in normal human T lymphocytes</title><source>Proc Natl Acad Sci USA</source><year>1985</year><volume>82</volume><fpage>6281</fpage><lpage>6285</lpage>
<author><surname>Kim</surname> <given-names>HP</given-names> </author><author><surname>Imbert</surname> <given-names>J</given-names> </author><author><surname>Leonard</surname> <given-names>WJ</given-names> </author><title>Both integrated and differential regulation of components of the IL-2/IL-2 receptor system</title><source>Cytokine Growth Factor Rev</source><year>2006</year><volume>17</volume><fpage>349</fpage><lpage>366</lpage>
<author><surname>Sancho</surname> <given-names>D</given-names> </author><author><surname>Gomez</surname> <given-names>M</given-names> </author><author><surname>Sanchez-Madrid</surname> <given-names>F</given-names> </author><title>CD69 is an immunoregulatory molecule induced following activation</title><source>Trends Immunol</source><year>2005</year><volume>26</volume><fpage>136</fpage><lpage>140</lpage>
<author><surname>Testi</surname> <given-names>R</given-names> </author><author><surname>D'Ambrosio</surname> <given-names>D</given-names> </author><author><surname>De</surname> <given-names>MR</given-names> </author><author><surname>Santoni</surname> <given-names>A</given-names> </author><title>The CD69 receptor: a multipurpose cell-surface trigger for hematopoietic cells</title><source>Immunol Today</source><year>1994</year><volume>15</volume><fpage>479</fpage><lpage>483</lpage>
<author><surname>Boulanger</surname> <given-names>A</given-names> </author><author><surname>Liu</surname> <given-names>S</given-names> </author><author><surname>Yu</surname> <given-names>S</given-names> </author><author><surname>Redmond</surname> <given-names>TM</given-names> </author><title>Sequence and structure of the mouse gene for RPE65</title><source>Mol Vis</source><year>2001</year><volume>7</volume><fpage>283</fpage><lpage>287</lpage>
<author><surname>Bennicelli</surname> <given-names>J</given-names> </author><author><surname>Wright</surname> <given-names>JF</given-names> </author><author><surname>Komaromy</surname> <given-names>A</given-names> </author><title>Reversal of blindness in animal models of leber congenital amaurosis using optimized AAV2-mediated gene transfer</title><source>Mol Ther</source><year>2008</year><volume>16</volume><fpage>458</fpage><lpage>465</lpage>
<author><surname>Thomas</surname> <given-names>CE</given-names> </author><author><surname>Ehrhardt</surname> <given-names>A</given-names> </author><author><surname>Kay</surname> <given-names>MA</given-names> </author><title>Progress and problems with the use of viral vectors for gene therapy</title><source>Nat Rev Genet</source><year>2003</year><volume>4</volume><fpage>346</fpage><lpage>358</lpage>
<author><surname>Petry</surname> <given-names>H</given-names> </author><author><surname>Brooks</surname> <given-names>A</given-names> </author><author><surname>Orme</surname> <given-names>A</given-names> </author><title>Effect of viral dose on neutralizing antibody response and transgene expression after AAV1 vector re-administration in mice</title><source>Gene Ther</source><year>2008</year><volume>15</volume><fpage>54</fpage><lpage>60</lpage>
<author><surname>Bennett</surname> <given-names>J</given-names> </author><title>Immune response following intraocular delivery of recombinant viral vectors</title><source>Gene Ther</source><year>2003</year><volume>10</volume><fpage>977</fpage><lpage>982</lpage>
<author><surname>Chen</surname> <given-names>J</given-names> </author><author><surname>Wu</surname> <given-names>Q</given-names> </author><author><surname>Yang</surname> <given-names>P</given-names> </author><author><surname>Hsu</surname> <given-names>HC</given-names> </author><author><surname>Mountz</surname> <given-names>JD</given-names> </author><title>Determination of specific CD4 and CD8 T cell epitopes after AAV2- and AAV8-hF.IX Gene Therapy</title><source>Mol Ther</source><year>2006</year><volume>13</volume><fpage>260</fpage><lpage>269</lpage>
<author><surname>McTiernan</surname> <given-names>CF</given-names> </author><author><surname>Mathier</surname> <given-names>MA</given-names> </author><author><surname>Zhu</surname> <given-names>X</given-names> </author><title>Myocarditis following adeno-associated viral gene expression of human soluble TNF receptor (TNFRII-Fc) in baboon hearts</title><source>Gene Ther</source><year>2007</year><volume>14</volume><fpage>1613</fpage><lpage>1622</lpage>
<author><surname>Vandenberghe</surname> <given-names>LH</given-names> </author><author><surname>Wang</surname> <given-names>L</given-names> </author><author><surname>Somanathan</surname> <given-names>S</given-names> </author><title>Heparin binding directs activation of T cells against adeno-associated virus serotype 2 capsid</title><source>Nat Med</source><year>2006</year><volume>12</volume><fpage>967</fpage><lpage>971</lpage>
<author><surname>Perabo</surname> <given-names>L</given-names> </author><author><surname>Goldnau</surname> <given-names>D</given-names> </author><author><surname>White</surname> <given-names>K</given-names> </author><title>Heparan sulfate proteoglycan binding properties of adeno-associated virus retargeting mutants and consequences for their in vivo tropism</title><source>J Virol</source><year>2006</year><volume>80</volume><fpage>7265</fpage><lpage>7269</lpage>
<author><surname>Jiang</surname> <given-names>H</given-names> </author><author><surname>Couto</surname> <given-names>LB</given-names> </author><author><surname>Patarroyo-White</surname> <given-names>S</given-names> </author><title>Effects of transient immunosuppression on adenoassociated, virus-mediated, liver-directed gene transfer in rhesus macaques and implications for human gene therapy</title><source>Blood</source><year>2006</year><volume>108</volume><fpage>3321</fpage><lpage>3328</lpage>
<author><surname>Wang</surname> <given-names>Z</given-names> </author><author><surname>Kuhr</surname> <given-names>CS</given-names> </author><author><surname>Allen</surname> <given-names>JM</given-names> </author><title>Sustained AAV-mediated dystrophin expression in a canine model of Duchenne muscular dystrophy with a brief course of immunosuppression</title><source>Mol Ther</source><year>2007</year><volume>15</volume><fpage>1160</fpage><lpage>1166</lpage>